Six-minute stepper test to assess effort intolerance in interstitial lung diseases.
Six-minute stepper test to assess effort intolerance in interstitial lung diseases. Sarcoidosis Vasc Diffuse Lung Dis. 2012 Oct;29(2):107-12 Authors: Delourme J, Stervinou-Wemeau L, Salleron J, Grosbois JM, Wallaert B Abstract The six-minute stepper test (6MST) is a new test for evaluating exercise tolerance. Unlike the six-minute walk test (6MWT) it can be carried out in a limited space. The aim of this study was to compare the 6MST and the 6MWT in patients with various diffuse interstitial lung disease (ILD). 6MWT and 6MST were performed the same day in 84 patients with various ILD. The covered distance during 6MWT was compared to the number of steps during the 6MST. We also compared heart rate, oxygen saturation, dyspnoea and leg tiredness on a Borg scale. All the patients successfully completed the tests, and tolerance was considered good. The number of steps completed in the 6MST was strongly correlated with the distance walked in the 6MWT (r2 = 0.5; p
CONCLUSIONS: Lower levels of confidence in IPF patients are associated with higher levels of depression and fatigue and worse HRQOL. Efforts should be made to improve patient confidence to assess the impact on HRQOL. PMID: 28079846 [PubMed - in process]
CONCLUSIONS: Both sarcoidosis and IPF patients suffer with fatigue, although sarcoidosis patients tended towards reporting more severe fatigue scores, suggesting a subgroup with severe fatigue. The fatigue experienced by the two groups appears to be different; sarcoidosis patients report greater frequency of mental fatigue whereas IPF patients appear to suffer exhaustion, potentially related to dyspnoea. Dyspnoea and sleepiness scores modeled the majority of fatigue in the IPF group, whereas no single factor was able to predict fatigue in sarcoidosis. PMID: 27537715 [PubMed - as supplied by publisher]
ConclusionsCryo-TBB may be a reliable diagnostic tool in ILD, dispensing the need for a SLB in most cases. Severe complications may occur less frequently than in SLB. Modifications of the procedure may lead to further risk reduction. PMID: 27055830 [PubMed - in process]
CONCLUSION: In this small, retrospective study of chronic CTD-ILD, RTX was not associated with changes in FVC% or corticosteroid-sparing effects. Controlled, prospective studies are needed to more confidently define the effects of RTX in CTD-ILD. (Sarcoidosis Vasc Diffuse Lung Dis 2015; 32: 296-304). PMID: 26847096 [PubMed - in process]
CONCLUSIONS: Lung biopsy was performed mostly by VATS, with limited morbidity, and was effective in yielding a specific histologic diagnosis in the vast majority of undefined ILD cases. To optimize the outcome of surgical biopsy for specific diagnosis of ILD, this procedure should be performed only exceptionally in patients with critical respiratory illness as postoperative mortality risk in these subjects is exceedingly high. PMID: 26422571 [PubMed - in process]
CONCLUSIONS: Treatment with RTX resulted in an objective, measurable improvement in pulmonary function and/or radiological severity for the majority of patients included in the series. This was statistically significant despite the small numbers included. These results indicate a positive response to RTX with few complications of treatment. . PMID: 26422566 [PubMed - in process]
We report a rare case of near fatal DIP with recurrent bilateral tension pneumothorax despite of corticosteroid maintenance therapy. Clinical and radiological findings improved with surgical intervention in addition to combination therapy with prednisolone and clarithromycin. The patient has remained in an improved state and has been receiving prednisolone and clarithromycin for 9 months. (Sarcoidosis Vasc Diffuse Lung Dis 2015; 32: 167-171). PMID: 26278697 [PubMed - in process]
CONCLUSIONS: We observed a high prevalence of osteoporosis and osteopenia among newly diagnosed ILD patients. Our findings suggest that there is a substantially increased risk of osteoporosis and that early screening and aggressive treatment with various anti-bone resorptive therapies are necessary in ILD patients. (Sarcoidosis Vasc Diffuse Lung Dis 2015; 32: 151-159). PMID: 26278695 [PubMed - in process]
Authors: Kishaba T Abstract Idiopathic Pulmonary Fibrosis (IPF) is relentless progressive interstitial lung disease (ILD) of unknown etiology. Main pathogenesis is aberrant recovery of epithelial injury and collagen deposition. Majority of IPF patients have been elderly men with smokers. However, there are important differential diagnosis such as fibrotic non-specific interstitial pneumonia (NSIP), Connective Tissue Disease (CTD) associated ILD, chronic hypersensitivity pneumonia (CHP). Clinical point of view, non-productive cough and progressive exertional dyspnea are main symptoms. In addition, scalene musc...
Authors: Bendstrup E, Maher TM, Manali ED, Wijsenbeek M Abstract According to current international guidelines the idiopathic interstitial pneumonias (IIPs) are grouped into three categories; major, rare, and unclassifiable. Idiopathic pulmonary fibrosis (IPF) is one of the major IIPs and has been recognised as a distinct clinical entity since 2001. This has led to significant advances in our understanding and treatment of the disease and to the identification of new therapeutic targets. While multidisciplinary team assessment yields a definite diagnosis in many cases of interstitial lung disease (ILD), 15-25% of p...